ImmunityBio Inc. (IBRX)
IBRX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1326110/000132611026000030/0001326110-26-000030-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IBRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001326110 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $113.3M |
| Net income | -$351.4M |
| Operating income | -$256.0M |
| Net margin | -310.2% |
| Operating margin | -226.0% |
| Revenue growth | +668.3% |
| Cash | $88.3M |
| Total assets | $501.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 56.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result of continuing anticipated operating cash outflows as we commercialize our approved product and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support." | 10-Q 2026-11-09 |
| Cash and burn | $45.1M cash; operating cash flow -$71.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,063,826,073 (2026-11-03); 984,965,179 a year earlier; 667,705,368 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-29 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Diego, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $8.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $48.8M | -$184.6M | -$75.3M | $45.1M | No debt tags | $182.6M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $51.2M | -$230.4M | -$66.5M | $75.7M | No debt tags | $165.8M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $44.2M | -$632.8M | -$75.4M | $205.2M | $884K | $141.0M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $38.3M | -$61.9M | -$70.4M | $88.3M | $1.8M | $113.3M | 10-K 2026-02-23 |
| Q3 2025 2025-09-30 | $32.1M | -$67.3M | -$68.9M | $60.2M | $2.6M | $82.6M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $26.4M | -$92.6M | -$79.7M | $137.7M | No debt tags | $56.6M | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | $16.5M | -$129.6M | -$85.9M | $60.7M | No debt tags | $31.2M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $7.6M | -$59.2M | -$85.1M | $143.4M | $1.2M | $14.7M | 10-K 2026-02-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-29 |
| Latest annual report | 10-K | 2026-02-23 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 557 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -30.3% |
| 1 month | -38.6% |
| 3 months | -21.3% |
| Year to date | +204.0% |
| 1 year | +201.0% |
| From 52-week high | -47.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KOD | Kodiak Sciences Inc | $100.73 | -9.41% | $6.6B |
| IMVT | Immunovant Inc. | $33.28 | -2.63% | $6.9B |
| TWST | Twist Bioscience Corporation | $105.04 | -5.88% | $7.0B |
| SRRK | Scholar Rock Holding Corporation | $44.54 | +3.09% | $5.4B |
| CGON | CG Oncology Inc. | $84.78 | +13.95% | $7.6B |
| KRYS | Krystal Biotech Inc. | $297.90 | -2.40% | $8.8B |
| ADPT | Adaptive Biotechnologies Corporation | $27.87 | -4.03% | $4.5B |
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier